← Patent-cliff monitor small molecule PREVYMIS LETERMOVIR
Loss of exclusivity August 2031 FDA regulatory exclusivity expiry
Company MERCK SHARP AND DOHME CORP
Drug detail Brand name PREVYMIS Active ingredient LETERMOVIR Strength 480MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval November 2017 Marketing status RX
Listed patents Patent Expires Type RE46791 January 2029 substance, product
Regulatory exclusivity Code Expires ODE-495 August 2031 ODE-497 August 2031 ODE-423 June 2030 NPP August 2027 D-189 August 2026 I-916 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.